NEWS
The 2025 AD Scientific Index is here—explore updated university and researcher rankings!
New! Young University / Institution Rankings 2025
New! The 2025 Edition of the AD Scientific Index is now live!
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
"Exciting Update! The 2025 Edition of the AD Scientific Index is now live!
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Top Lists
Danny Rischin
Peter Maccallum Cancer Centre - Melbourne / Australia
Others
AD Scientific Index ID: 4393806
-
Edit Form
Registration, Add Profile,
Premium Membership
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Danny Rischin's MOST POPULAR ARTICLES
1-)
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancerM Fukuoka, S Yano, G Giaccone, T Tamura, K Nakagawa, JY Douillard, ...Journal of clinical oncology 41 (6), 1162-1171, 202338802023
2-)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised …B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G de Castro Jr, ...The Lancet 394 (10212), 1915-1928, 201913572019
3-)
PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinomaMR Migden, D Rischin, CD Schmults, A Guminski, A Hauschild, KD Lewis, ...New England Journal of Medicine 379 (4), 341-351, 201810052018
4-)
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five …J Baselga, D Rischin, M Ranson, H Calvert, E Raymond, DG Kieback, ...Journal of clinical oncology 20 (21), 4292-4302, 200210202002
5-)
Prognostic Significance of p16INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III TrialD Rischin, RJ Young, R Fisher, SB Fox, QT Le, LJ Peters, B Solomon, ...Journal of clinical oncology 28 (27), 4142-4148, 20108812010
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept